Fig. 4From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s diseasePercentage changes in median cerebrospinal fluid biomarker levels for Aβ1–42, p-tau, t-tau, and neurogranin. *p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.0001. Aβ Amyloid-beta, p-tau Phosphorylated tau 181Back to article page